PurMinds is an innovative precision NeuroMedicine company pursuing breakthrough solutions to neurodegenerative diseases by progressing a robust clinical pipeline derived from multi-omics studies and an AI and data driven drug discovery platform.
PurMinds drug development pipeline includes small molecule, psychedelic and other therapeutic candidates. Our near- and medium-term milestones include multiple pre-clinical studies, clinical trials and patent filings targeting diseases such as ALS, Alzheimer’s and Frontotemporal Dementia, etc.
PurMinds' PurPrecision NeuroMedicine Discovery Platform is powered by leading-edge neuronal screening technologies, multi-omics studies, big data and machine learning engines. It can generate unique molecular signatures of the diseases and novel therapeutic targets that directly inform and continuously refine and de-risk our pipeline.
PurMinds owns a neurolab with Health Canada approved license for Controlled Substances (Narcotics & psychedelic